375
Participants
Start Date
August 6, 2021
Primary Completion Date
December 31, 2022
Study Completion Date
March 31, 2023
TQB2450 injection
1200mg injection once every 3 week
Anlotinib Hydrochloride Capsules
12mg capsule once daily
Pembrolizumab injection
200mg injection once every 3 week
Placebo
Placebo capsule once daily
NOT_YET_RECRUITING
China-Japan Friendship Hospital, Beijing
NOT_YET_RECRUITING
Shanghai Chest Hospital, Shanghai
NOT_YET_RECRUITING
The Ninth Affiliated People's Hospital of Shanghai Jiao Tong University, School of Medicine, Shanghai
NOT_YET_RECRUITING
Tianjin Cancer Hospital, Tianjin
RECRUITING
Affiliated Hospital of Guangdong Medical University, Zhangjiang
NOT_YET_RECRUITING
Beijing Chest Hospital, Capital Medical University, Beijing
NOT_YET_RECRUITING
Peking University Third Hospital, Beijing
NOT_YET_RECRUITING
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
General Hospital of Tianjin Medical University, Tianjin
NOT_YET_RECRUITING
Tianjin Chest Hospital, Tianjin
NOT_YET_RECRUITING
Affiliated Tumor Hospital of Chongqing University, Chongqing
NOT_YET_RECRUITING
Three Gorges Hospital of Chongqing University, Chongqing
NOT_YET_RECRUITING
Southern Hospital of Southern Medical University, Guangzhou
NOT_YET_RECRUITING
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
Zhujiang Hospital of Southern Medical University, Guangzhou
NOT_YET_RECRUITING
Zhujiang Hospital of Southern Medical University, Guangzhou
NOT_YET_RECRUITING
The Fifth Central Hospital of Tianjin, Tianjin
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY